Cervical Insufficiency: Diagnosis, Cerclage, Progesterone, and Pessary in Preterm Birth Prevention

Cervical Insufficiency: Diagnosis, Cerclage, Progesterone, and Pessary in Preterm Birth Prevention

📖 16 min read🩺 Obstetrics & Gynecology👤 gomdori, MD🔬 ACOG / SMFM 2024

Executive Summary

Cervical insufficiency is the inability of the uterine cervix to retain a pregnancy in the second trimester in the absence of contractions or labor. Diagnosis rests on (1) history of ≥3 painless second-trimester losses with cervical dilation in the absence of bleeding/contractions/abruption; (2) transvaginal ultrasound demonstrating short cervical length <25 mm before 24 weeks in singleton with prior preterm birth, and (3) physical examination showing painless dilation in the second trimester. Three cerclage indications — history-indicated (12–14 weeks), ultrasound-indicated (16–23+6 weeks for cervical length <25 mm with prior spontaneous preterm birth <34 weeks), and physical-exam-indicated (rescue, up to 23+6 weeks). Vaginal progesterone 200 mg suppository nightly reduces preterm birth in singletons with short cervix <25 mm without prior preterm birth. Arabin pessary is an option in selected centers. Combined cerclage + progesterone may benefit highest-risk patients.

0.1–1%
Population prevalence
25 mm
TVUS short-cervix threshold
23+6 wk
Cerclage upper gestational limit
30%
Recurrence without intervention

1. Pathophysiology & Definition

The cervix functions as a structural barrier maintaining intrauterine contents during pregnancy. Its mechanical integrity derives from a dense extracellular matrix rich in cross-linked type I collagen, type III collagen, elastin, and proteoglycans (decorin, biglycan), with smooth muscle accounting for only ~10–15% of cervical stromal mass. Cervical remodeling through pregnancy progresses through four overlapping phases: softening (early gestation), ripening (third trimester), dilation (labor), and postpartum repair. In cervical insufficiency, the softening and ripening phases initiate prematurely — typically without painful contractions.

The pathophysiologic spectrum spans:

  • True structural cervical insufficiency — congenital connective tissue defects (Ehlers-Danlos, hypermobility spectrum), in-utero diethylstilbestrol exposure (now historical), uterine anomalies, or acquired weakness from prior cervical surgery (LEEP, cold-knife conization, repeated mechanical dilation, large laceration during prior delivery).
  • Inflammation-mediated premature ripening — subclinical chorioamnionitis driven by ascending genital tract infection (Ureaplasma, group B streptococcus, bacterial vaginosis–associated organisms) prematurely activates matrix metalloproteinases MMP-1, MMP-8, and MMP-9, accelerating collagen degradation and cervical funneling.
  • Idiopathic / multifactorial — the majority. Likely reflects an interplay of constitutional connective tissue properties, subclinical inflammation, and progesterone receptor signaling.

The functional cervical length curve in normal pregnancy plateaus at approximately 35–40 mm through 24 weeks, then progressively shortens. A length below the 10th percentile for gestational age (≈25 mm at 22–24 weeks in singletons) defines short cervix and is a powerful predictor of spontaneous preterm birth — risk approximately 6× elevated when cervical length is <25 mm at midtrimester ultrasound.

ⓘ
Distinguishing terminology. Cervical insufficiency (functional definition) ≠ short cervix on ultrasound (anatomic finding). Short cervix is a risk factor; cervical insufficiency is the clinical syndrome. Many short-cervix patients do not have insufficiency, and a normal-length cervix at one timepoint does not exclude future insufficiency.
Cervical Insufficiency — Pregnancy Cervix Changes Friedman cervical dilation curve showing latent and active labor phases Cervical Insufficiency — Pregnancy Cervix Changes 0 cm 2 cm 4 cm 6 cm 8 cm 10 cm 0h 4h 8h 12h 16h 20h 24h Cervical Dilation (cm) Time (hours) LATENT PHASE ACTIVE PHASE 2ND STAGE Nulliparous Multiparous
Cervical Insufficiency — Cervix Length & Funneling

2. Diagnostic Criteria & TVUS Surveillance

ACOG / SMFM diagnostic criteria

Diagnostic routeCriteriaAction
History-indicated≥3 prior painless second-trimester losses (16–24 wk) with cervical dilation in the absence of contractions, abruption, or chorioamnionitisPlan history-indicated cerclage at 12–14 wk in subsequent pregnancy
Ultrasound-indicatedSingleton, prior spontaneous preterm birth <34 wk, AND cervical length <25 mm before 24 wkOffer cerclage at 16–23+6 wk + vaginal progesterone
Physical-exam-indicated (rescue)Painless cervical dilation ≥1 cm on speculum or digital exam at <24 wk without preterm labor or chorioamnionitisConsider rescue cerclage up to 23+6 wk after exclusion of infection/abruption
Universal short-cervix screening: ACOG recommends consideration of universal mid-trimester (18–24 wk) cervical length screening in ALL singletons during anatomy ultrasound — to identify candidates for vaginal progesterone if cervical length <25 mm.

Transvaginal ultrasound technique

TVUS is the gold standard for cervical length assessment. Key technical requirements:

  1. Empty maternal bladder (full bladder elongates the cervix and falsely reassures).
  2. Patient supine, knees flexed; insert probe with minimal pressure to avoid compressing the cervix.
  3. Identify internal os, external os, and cervical canal in midsagittal view; the canal should appear as a thin echogenic line.
  4. Measure shortest length from internal os to external os along the canal (not a straight line if the canal is curved).
  5. Apply transfundal pressure for 15 seconds — if dynamic shortening or funneling appears, document the new length.
  6. Repeat 3 measurements; report the shortest reproducible value.

Funneling is dilation of the internal os with protrusion of membranes into the canal — described as T (no funnel), Y, V, or U shape (progressively wider). U-shape funneling with cervical length <15 mm carries the highest preterm birth risk.

TVUS cervical funnel progression — T, Y, V, U shapes Four progressive stages of cervical funneling on transvaginal ultrasound: T (closed internal os), Y (early funnel), V (V-shaped funnel), U (advanced U-shaped funnel) with associated risk levels. Cervical Funnel Progression on TVUS T-shape Closed internal os CL ~35–40 mm Normal Y-shape Early funnel CL ~25–30 mm Borderline V-shape V-funnel CL <25 mm High risk U-shape U-funnel CL <15 mm Highest risk Cervical canal in dark blue; surrounding myometrium not shown
TVUS funnel morphology progresses from T (closed internal os) through Y, V, to U-shape; U-funneling with cervical length <15 mm carries the highest preterm birth risk and triggers immediate cerclage consideration.
Cerclage Categories Comparison table: Cerclage Categories History-indicated US-indicated Exam-indicated (rescue) Transabdominal cerclage Contraindications Description ≥3 prior 2nd-trimester losses; place at 12-14 weeks Singleton + prior preterm + cervical length <25mm before 24 weeks Painless dilation + visible membranes; emergent For failed transvaginal; placed pre-conception or early pregnancy Active labor, infection, ruptured membranes, fetal demise
Cerclage Indications

3. Cerclage: Indications & Technique

Surgical approaches

ProcedureApproachSuture materialNotes
McDonaldVaginal — purse-string at cervicovaginal junctionMersilene 5 mm tapeMost common; technically simpler; removed at 36–37 wk
ShirodkarVaginal — submucosal placement higher on cervix after bladder advancementMersilene 5 mm tapeHigher placement may have slightly better outcomes; technically more demanding
Transabdominal cerclageLaparotomy or laparoscopy — placed at cervicoisthmic junctionMersilene tapeReserved for failed transvaginal cerclage or absent vaginal cervix; requires cesarean delivery
Pre-conception transabdominal cerclage may be performed laparoscopically and left in situ between pregnancies — increasingly used in patients with prior failed transvaginal cerclage.

Three cerclage indications

1. History-indicated (prophylactic) cerclage

Performed at 12–14 weeks in patients with classic history of recurrent painless mid-trimester loss. Pre-procedure: confirm viable singleton pregnancy, normal anatomic survey, exclude fetal anomalies, screen for and treat any vaginal infection. Anesthesia: regional (spinal) preferred over general. Removed at 36–37 weeks unless preterm labor, PPROM, or chorioamnionitis intervenes.

2. Ultrasound-indicated cerclage

Performed in patients meeting BOTH of: (a) singleton with prior spontaneous preterm birth <34 weeks, AND (b) cervical length <25 mm before 24 weeks. The MFMU Cerclage trial and Berghella meta-analyses support significant preterm-birth reduction in this population. Cerclage placement is at 16–23+6 weeks based on TVUS surveillance every 1–2 weeks. Combine with vaginal progesterone if not already initiated.

3. Physical-exam-indicated (rescue) cerclage

Indicated when speculum/digital examination at <24 weeks reveals painless cervical dilation ≥1 cm with or without visible membranes — in the absence of preterm labor, chorioamnionitis, abruption, or PPROM. Pre-procedure exclusion: amniocentesis to exclude subclinical chorioamnionitis is considered in high-risk situations (prior failed cerclage, suspicious clinical findings); WBC, glucose, gram stain, IL-6, and cultures are interpreted together. Reverse Trendelenburg position, bladder filling to push membranes upward, and rescue suture placement may achieve gestational prolongation of 7–13 weeks in observational studies.

⚠
Cerclage contraindications. Active labor, ruptured membranes (PPROM), chorioamnionitis, vaginal bleeding suggesting abruption, lethal fetal anomaly, intrauterine fetal demise, fetal distress not amenable to intervention, advanced cervical dilation with prolapsing membranes the surgeon cannot reduce. Multifetal gestation is no longer an absolute contraindication but evidence for benefit is limited and selective.
CI Stepwise Surgical stepper: CI Stepwise CI Stepwise 1 Risk assessment History of 2nd trimester loss, preterm birth, cervical surgery; serial TVUS in subsequent pregnancy 2 Vaginal progesterone Vaginal progesterone 200mg suppository or 90mg gel daily 16-36 weeks for short cervix without prior 3 History-indicated cerclage Place at 12-14 weeks; McDonald (vaginal) most common; Shirodkar alternative 4 US-indicated cerclage Place when cervical length <25mm + prior preterm + singleton; up to 24 weeks 5 Exam-indicated (rescue) Place if painless dilation + membranes visible; high-risk procedure; antibiotics 6 Pessary Arabin pessary alternative; mixed evidence; non-surgical
CI Algorithm

4. Vaginal Progesterone & Pessary

Vaginal progesterone

Vaginal progesterone is recommended for singleton patients with incidentally discovered short cervix <25 mm at midtrimester TVUS without prior preterm birth. Standard regimen: 200 mg micronized progesterone vaginal suppository nightly initiated upon diagnosis through 36+6 weeks. Alternative: 90 mg progesterone gel daily.

Mechanism — progesterone maintains uterine quiescence by inhibiting prostaglandin synthesis, reducing myometrial gap junction formation, suppressing oxytocin receptor expression, and stabilizing the cervical extracellular matrix. The PREGNANT trial and meta-analyses demonstrate ~45% relative reduction in preterm birth <33 weeks in singletons with short cervix.

Preventive interventionIndicationEvidence
Vaginal progesterone 200 mg HSSingleton + short cervix <25 mm + no prior preterm birthMultiple RCTs + Cochrane meta-analysis support; ~45% PTB reduction
Cerclage + progesteroneSingleton + short cervix <25 mm + prior preterm birth <34 wkCombined approach favored in highest-risk group
17α-hydroxyprogesterone caproate (17-OHPC) IMWITHDRAWN — Makena withdrawn from US market April 2023 after PROLONG trial failureNo longer recommended; vaginal progesterone preferred
Arabin pessarySingleton, short cervix; selected centersConflicting RCTs; ProTWIN positive in twins, PECEP positive in singletons, OPPTIMUM/PROMISE neutral; not first-line in US
Bed rest, activity restrictionHistorically prescribedNO benefit; risk of VTE, deconditioning, psychosocial harm — DO NOT prescribe

Arabin pessary

The Arabin cervical pessary is a flexible silicone cup that surrounds the cervix and theoretically redirects intrauterine pressure away from the internal os, reducing mechanical stress on the lower uterine segment. Insertion is an office procedure; no anesthesia is required. Removal at 37 weeks or with PPROM/labor onset.

Evidence remains conflicting — the original ProTWIN (Goya, twins) and PECEP (Goya, singletons) trials reported significant reductions in preterm birth, but the larger OPPTIMUM, PROMISE, and PESAPRO trials found no benefit. The 2024 ACOG Practice Bulletin notes pessary as an option but does not endorse routine use; SMFM advises against routine pessary use in singletons.

✓ Pearl

For a patient with prior spontaneous preterm birth <34 weeks who reaches 16 weeks in the next pregnancy with a normal cervical length, do NOT place prophylactic cerclage. Instead initiate vaginal progesterone and serial TVUS every 2 weeks from 16 to 24 weeks. If cervical length falls below 25 mm, place ultrasound-indicated cerclage. This avoids unnecessary surgery while maintaining vigilance.

✗ Pitfall

17-OHPC (Makena) was withdrawn from the US market in April 2023 after the PROLONG confirmatory trial failed to reproduce the original Meis 2003 finding. Do NOT prescribe. Vaginal progesterone is the only progesterone-class intervention currently supported by guidelines for preterm-birth prevention in singletons.

5. Special Populations & Complications

Special populations

PopulationApproachNotes
Twin gestation, short cervix <25 mmVaginal progesterone (200 mg HS) is reasonable; cerclage controversialRoutine cerclage NOT indicated; selective cerclage for cervix <15 mm may benefit
Twin gestation, prior preterm birthVaginal progesterone; cerclage individualizedLess clear benefit than singletons
Acute cervical insufficiency >23+6 wkNO cerclage; tocolysis, antenatal corticosteroids, magnesium for neuroprotection if 24–32 wkRisk-benefit shifts toward conservative management
Prior LEEP / cone biopsyTVUS surveillance every 2 weeks from 16–24 weeks; ultrasound-indicated cerclage if <25 mmRisk increases with cone depth >15 mm and repeated procedures
Mullerian anomalies (unicornuate, septate)Higher baseline preterm birth risk; TVUS surveillanceCerclage benefit uncertain; individualize
PPROM at 16–24 weeksCerclage in situ → typically removed; expectant management of PPROMLeaving cerclage in place increases chorioamnionitis risk

Complications of cerclage

  • Chorioamnionitis — 1–9%; higher in physical-exam-indicated rescue cerclage (10–30%).
  • PPROM — 1–18% across indication groups; higher in rescue cerclage.
  • Preterm labor / contraction induction — typically transient; managed expectantly or with tocolysis.
  • Cervical laceration — at delivery if cerclage is not removed in time, especially if labor onset is rapid.
  • Bladder injury, hemorrhage, suture displacement — uncommon.
  • Cervical stenosis or dystocia — rare with timely removal.

Cerclage removal

Plan removal at 36+0 to 37+0 weeks. Earlier removal indicated for: preterm labor unresponsive to tocolysis, PPROM, chorioamnionitis, severe vaginal bleeding, or non-reassuring fetal status. McDonald cerclage removal is typically performed in clinic without anesthesia; Shirodkar may require regional anesthesia. Transabdominal cerclage is left in place permanently and the patient is delivered by cesarean — between pregnancies the cerclage remains.

📍
When to refer to MFM (Maternal-Fetal Medicine). (1) Prior failed cerclage with subsequent preterm loss. (2) Suspected need for transabdominal cerclage. (3) Cervical insufficiency in twin or triplet pregnancy. (4) Müllerian anomaly with cervical insufficiency history. (5) Diagnostic uncertainty between cervical insufficiency and preterm labor. (6) Acute cervical dilation with prolapsing membranes >3 cm. (7) Genetic / connective tissue disorders (Ehlers-Danlos, Marfan).

6. Frequently Asked Questions

Should every pregnancy receive universal mid-trimester cervical length screening?
ACOG and SMFM recommend that universal mid-trimester (typically 18–24 weeks at the time of routine anatomy ultrasound) cervical length screening in singletons is reasonable. The motivation is to identify the substantial subset of women with a short cervix <25 mm and no prior preterm birth — the population for whom vaginal progesterone is most beneficial. Programs implementing universal screening combined with treatment have shown reductions in preterm birth at the population level. Screening must be performed transvaginally (transabdominal screening systematically overestimates length).
Is a history-indicated cerclage always required after one prior second-trimester loss?
Not always. A single second-trimester loss may not meet the strict diagnostic criteria of cervical insufficiency if the loss was associated with rupture of membranes, contractions, abruption, or chorioamnionitis. In a patient with one prior loss whose history is ambiguous, the standard approach is serial TVUS surveillance every 2 weeks from 16 to 24 weeks plus vaginal progesterone — placing ultrasound-indicated cerclage if the cervix shortens below 25 mm. History-indicated cerclage is reserved for patients with a clear-cut clinical picture of recurrent painless loss with cervical dilation in absence of contractions.
What is the upper gestational age limit for placing cerclage?
23+6 weeks is the conventional upper limit. Beyond 24 weeks, fetal viability is established, and cerclage carries higher risk of inducing labor, chorioamnionitis, or membrane rupture without compensating benefit. Above 24 weeks, the management focus shifts to tocolysis, antenatal corticosteroids for fetal lung maturity, magnesium sulfate for fetal neuroprotection (24–32 weeks), and bed rest in selected cases. Some centers extend rescue cerclage to 24+0 in highly selected cases, but this is institutional and not standard.
Should we still use 17-hydroxyprogesterone caproate (17-OHPC, Makena)?
No. 17-OHPC (Makena) was withdrawn from the US market in April 2023 by the FDA after the PROLONG confirmatory trial failed to reproduce the preterm birth reduction observed in the original Meis 2003 trial. Vaginal progesterone is now the only progesterone-class agent recommended for preterm-birth prevention in singletons with short cervix. Do not prescribe 17-OHPC. In international markets where 17-OHPC remains available, current consensus also discourages routine use given the negative confirmatory data.
Can a transabdominal cerclage be placed before pregnancy?
Yes — preconception transabdominal cerclage, typically placed laparoscopically, is increasingly used in women with prior failed transvaginal cerclage or those with absent/scarred vaginal cervix preventing transvaginal placement. The cerclage remains in situ between pregnancies, so it does not need to be replaced. All deliveries with abdominal cerclage in place must be by cesarean section. Compared to placement during pregnancy, preconception placement avoids gestational risks, may have a lower complication rate, and allows planning. Refer to MFM for evaluation.

S7. Practice Insights: Cervical Insufficiency Three-Indication Algorithm

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Painless mid-trimester cervical change is silent until it is advanced, and cerclage, progesterone, and pessary are not interchangeable answers to it — the dominant management failures cluster around four operational points: misclassifying patients into the wrong cerclage indication category (which drives the timing and approach), missing the mid-trimester cervical length surveillance window in high-risk patients, choosing cerclage when vaginal progesterone monotherapy would have worked (or vice versa), and undertreating short cervix in twin gestations where the evidence base is genuinely mixed. In experienced practice, four operational principles drive successful preterm birth prevention.

1. Three Cerclage Indication Categories

In practice, every cerclage decision begins with categorizing the patient into one of three established indications. History-indicated cerclage (formerly “elective”): patient with 3+ prior second-trimester pregnancy losses or preterm births in the setting of painless cervical dilation, with cerclage placed prophylactically at 13-14 weeks gestation. Ultrasound-indicated cerclage: patient with prior spontaneous preterm birth before 34 weeks plus current pregnancy with cervical length less than 25 mm before 24 weeks, with cerclage placed when short cervix is identified. Exam-indicated (rescue) cerclage: patient with cervical dilation 1-4 cm and visible membranes at 16-24 weeks gestation regardless of prior history. The category dictates timing and technique, and miscategorization is the dominant decision error.

2. TVUS Cervical Length Surveillance

In experienced hands, transvaginal cervical length measurement every 1-2 weeks between 16 and 24 weeks gestation is mandatory in high-risk patients: prior spontaneous preterm birth before 34 weeks, history of cervical surgery (LEEP, cone biopsy), Mullerian anomaly, multiple gestation in some protocols. Normal cervical length is ≥30 mm. Surveillance threshold for intervention: less than 25 mm before 24 weeks triggers consideration of cerclage or progesterone based on the indication category. Less than 10 mm warrants rescue cerclage consideration regardless of prior history. The standardized technique matters — transvaginal probe with empty bladder, three measurements taken with the shortest used, proper image quality with calibration markers visible.

3. Cerclage vs Vaginal Progesterone

In practice, the choice between cerclage and vaginal progesterone is driven by patient profile. Vaginal progesterone (200 mg suppository nightly) is appropriate for: singleton pregnancy WITHOUT prior preterm birth but with incidentally discovered short cervix less than 25 mm at 16-24 weeks. Cerclage (typically McDonald technique transvaginally) is appropriate for: singleton with prior spontaneous preterm birth less than 34 weeks AND current short cervix less than 25 mm; or the three-indication categories above. Combined cerclage plus progesterone may be considered in select high-risk patients but standard practice is either-or. Both approaches reduce preterm birth approximately 30-40% in appropriate populations.

4. Twin Gestation: Mixed Evidence

Twin gestations are a more difficult management space. Multiple studies have not consistently shown benefit from prophylactic cerclage in twin pregnancies with short cervix, and some early studies showed potential harm. In experienced practice, experienced clinicians now recommend: ultrasound-indicated cerclage in twins with cervical length less than 15 mm at less than 24 weeks (small subgroup analysis suggests benefit at this severe threshold); no routine cerclage for twins with cervical length 15-25 mm without other indications; vaginal progesterone has limited evidence in twins but is often used; pessary has had mixed trial results with some European data supporting use but US guidance has been more skeptical. clinicians document the shared decision-making with the patient about uncertainty in twin pregnancy management.

Illustrative Scenario: Ultrasound-Indicated Cerclage After Prior Preterm Birth

A woman in her early 30s G2P1 with prior spontaneous preterm birth at 28 weeks (her first pregnancy 2 years ago resulted in a NICU graduate now doing well) was followed at 16, 18, and 20 weeks with TVUS cervical length measurements. At 20 weeks, cervical length was 21 mm (down from 32 mm at 16 weeks), with normal placentation, no contractions, normal urinalysis.

She met ultrasound-indicated cerclage criteria. After shared decision-making about benefits/risks (~30-40% preterm birth reduction vs procedural risks of bleeding, infection, membrane rupture ~1%), she elected to proceed with McDonald cerclage placement at 20+4 weeks. Procedure was uncomplicated. She continued progesterone given the prior preterm history (combined approach in this high-risk subgroup). Cerclage was removed at 37+0 weeks. She delivered vaginally at 38+2 weeks, full-term healthy infant. Without intervention her prior trajectory predicted a 28-30 week recurrence; the gain of 10+ weeks of gestation transformed neonatal outcomes for this family.

Takeaway: Ultrasound-indicated cerclage for the prior-preterm patient with current short cervix is high-evidence and high-impact. Mid-trimester TVUS surveillance must be implemented in every high-risk pregnancy. The 30-40% relative risk reduction in preterm birth translates to substantial absolute risk reduction in this population.

Practice Pattern Refinements vs Standard Approach

  • Three cerclage indication categories: history (3+ losses, place 13-14 wk), ultrasound (prior preterm + CL<25mm, place when found), exam (rescue, dilation 1-4 cm 16-24 wk).
  • TVUS cervical length q1-2wk between 16-24 wk in high-risk patients (prior preterm, cervical surgery, Mullerian anomaly). <25 mm intervention threshold; <10 mm rescue.
  • Vaginal progesterone vs cerclage: progesterone for singleton no-prior-preterm with short cervix; cerclage for prior-preterm with short cervix. Combined for select high-risk.
  • Twin gestation: cerclage only at CL <15 mm; routine cerclage 15-25 mm not supported. Progesterone limited evidence; pessary mixed.
Cervical Insufficiency: 4-Pillar Framework Four-panel framework: three cerclage indications, TVUS surveillance, progesterone vs cerclage, twin gestation evidence. Cervical Insufficiency: 4-Pillar Framework 1. Three Cerclage Indications History-indicated (13-14 wk) 3+ second-trimester losses / preterm Ultrasound-indicated Prior preterm + CL < 25 mm at 16-24 wk Rescue / exam-indicated Dilation 1-4 cm + visible membranes Miscategorization = decision error 2. TVUS Cervical Length Surveillance Q1-2 wk 16-24 wk in high-risk: Prior spontaneous preterm < 34 wk Cervical surgery (LEEP, cone) Mullerian anomaly Normal: ≥ 30 mm Intervention: < 25 mm Rescue consideration: < 10 mm 3. Progesterone vs Cerclage Vaginal progesterone 200 mg nightly Singleton + no prior preterm + CL < 25 mm Cerclage (McDonald) Singleton + prior preterm + CL < 25 mm Both: ~30-40% PTB reduction Combined select high-risk; not routine 4. Twin Gestation: Mixed Evidence CL < 15 mm: cerclage considered CL 15-25 mm: routine cerclage NO Other options: Vaginal progesterone (limited evidence) Pessary (mixed trial results) Document shared decision uncertainty

Leave a Reply

Your email address will not be published. Required fields are marked *